Baillie Gifford & Co. Sells 10,159 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Baillie Gifford & Co. reduced its stake in TransMedics Group by 3.8%, owning approximately 0.77% of the company after selling 10,159 shares.
• TransMedics Group reported a significant earnings surprise, with $0.70 earnings per share for the latest quarter, surpassing analysts' expectations of $0.29.
• Analysts have a Moderate Buy rating on TransMedics Group, with price targets ranging from $129.00 to $150.00, indicating positive sentiment about the stock's future performance.

Baillie Gifford & Co. trimmed its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 3.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 259,677 shares of the company's stock after selling 10,159 shares during the quarter. Baillie Gifford & Co. owned approximately 0.77% of TransMedics Group worth $17,471,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after buying an additional 155 shares during the period. Campbell Newman Asset Management Inc. increased its position in shares of TransMedics Group by 1.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock worth $782,000 after purchasing an additional 166 shares during the last quarter. Hager Investment Management Services LLC increased its holdings in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after acquiring an additional 205 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of TransMedics Group by 1.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock worth $1,065,000 after acquiring an additional 256 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of TransMedics Group by 3.8% during the 1st quarter. Victory Capital Management Inc. now owns 8,365 shares of the company's stock worth $563,000 after acquiring an additional 308 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TMDX shares. Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Piper Sandler reiterated an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Canaccord Genuity Group upped their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $129.88.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David Weill sold 732 shares of the firm's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,418 shares of company stock worth $1,512,613. Insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded up $3.67 on Wednesday, hitting $108.50. 665,607 shares of the company traded hands, compared to its average volume of 1,330,419. The firm's 50-day simple moving average is $124.95 and its 200 day simple moving average is $94.13. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. The company has a market cap of $3.67 billion, a P/E ratio of 79.50 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.35 EPS. Analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.